Interventional Active not recruiting
NCT06571747 on ClinicalTrials.gov
Kaiser Permanente VACCination Improvement With Nudge-based CardiovAscular Targeted Engagement
- Sponsor: Kaiser Permanente Southern California (Pasadena)
- Enrollment: 3668428 (Actual)
- Study start: 2024-09-05 (Actual)
- Primary completion: 2025-05-01 (Actual)
- Study completion: 2026-03-31 (Estimated)
- Allocation: Randomized
- InterventionModel: Parallel
- Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
- PrimaryPurpose: Other
Brief Summary
In randomized clinical trials and observational studies, influenza vaccination is effective in reducing influenza-related illness and hospitalizations and potentially cardiovascular (CV) events and mortality in select populations. However, the potential population-level benefit of influenza vaccination is limited by its uptake. Novel implementation strategies to improve vaccination uptake are needed.
KP VACCINATE is a multicenter, sequential, individual-level randomized controlled implementation trial examining the effectiveness of a CV-focused nudging communication vs. usual care communication on influenza vaccination uptake among Kaiser Permanente Northern California (KPNC) and Kaiser Permanente Mid Atlantic States (KPMAS) eligible members during the 2024-2025 influenza season.
Conditions
- Cardiovascular Diseases
- Influenza
- Behavior, Social
Intervention / Treatment
- Behavioral: Cardiovascular-Focused Nudge Communication
Primary Outcome Measures
-
Proportion of participants with documented influenza vaccine receipt
(up to 8 months)
Proportion of participants with documented influenza vaccine receipt after randomization.
Countries
United States
Locations and Investigators
- Kaiser Permanente Northern California, Pleasanton, United States
- Kaiser Permanente Mid Atlantic States, Bethesda, United States
Study Officials
- Ankeet Bhatt, MD (Principal Investigator) — The Permanente Medical Group
- Benjamin Galper, MD (Principal Investigator) — Mid-Atlantic Permanente Medical Group